Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.

J Immunother Cancer · 2016 · PMC5109842 · PMID 27879974

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Clearance was a highly significant predictor of response, and the relationship between clearance and probability of OR was consistent across patients at all dose levels (Fig. 4 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.